Sign Up to like & get
recommendations!
0
Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16219
Abstract: Background/Aim: Treatment for advanced renal cell carcinoma (aRCC) comprises single agent or combinations of immune checkpoint inhibitors and/or anti-angiogenic agents. Pazopanib is a multitargeted anti-angiogenic tyrosine kinase inhibitor (TKI) approved as treatment for aRCC. We…
read more here.
Keywords:
bowel lipomatosis;
small bowel;
pazopanib;
finding patients ... See more keywords